Limits...
Advances in synthetic peptide immuno-regulatory epitopes.

Creticos PS - World Allergy Organ J (2014)

Bottom Line: Synthetic peptide immuno-regulatory epitopes (SPIRE) represent a new class of therapeutics for allergen immunotherapy that offer the potential to suppress the IgE-mediated allergic disease process through induction of T-cell tolerance.These synthetic T-cell-tolerizing peptides have been designed to induce immunologic tolerance via binding to MHC class II molecules on antigen presenting cells, with subsequent upregulation of regulatory T-cells.

View Article: PubMed Central - PubMed

Affiliation: Creticos Research Group, Crownsville, Maryland USA ; Division of Allergy & Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, Maryland USA.

ABSTRACT
Synthetic peptide immuno-regulatory epitopes (SPIRE) represent a new class of therapeutics for allergen immunotherapy that offer the potential to suppress the IgE-mediated allergic disease process through induction of T-cell tolerance. These synthetic T-cell-tolerizing peptides have been designed to induce immunologic tolerance via binding to MHC class II molecules on antigen presenting cells, with subsequent upregulation of regulatory T-cells.

No MeSH data available.


Related in: MedlinePlus

Delta changes in total rhinoconjunctivitis symptom scores for the treatment effect observed with Cat-SPIRE in the environmental exposure chamber.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4230367&req=5

Fig1: Delta changes in total rhinoconjunctivitis symptom scores for the treatment effect observed with Cat-SPIRE in the environmental exposure chamber.

Mentions: FigureĀ 1 displays the mean TRSS symptom scores at each 30-minute time point in the chamber over the 4 consecutive exposure days for the baseline EEC challenge and the 1-year EEC challenge, and in fact points out that the challenge performed at 1-year demonstrates the treatment effect to be stronger on successive days in the EEC [24].Figure 1


Advances in synthetic peptide immuno-regulatory epitopes.

Creticos PS - World Allergy Organ J (2014)

Delta changes in total rhinoconjunctivitis symptom scores for the treatment effect observed with Cat-SPIRE in the environmental exposure chamber.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4230367&req=5

Fig1: Delta changes in total rhinoconjunctivitis symptom scores for the treatment effect observed with Cat-SPIRE in the environmental exposure chamber.
Mentions: FigureĀ 1 displays the mean TRSS symptom scores at each 30-minute time point in the chamber over the 4 consecutive exposure days for the baseline EEC challenge and the 1-year EEC challenge, and in fact points out that the challenge performed at 1-year demonstrates the treatment effect to be stronger on successive days in the EEC [24].Figure 1

Bottom Line: Synthetic peptide immuno-regulatory epitopes (SPIRE) represent a new class of therapeutics for allergen immunotherapy that offer the potential to suppress the IgE-mediated allergic disease process through induction of T-cell tolerance.These synthetic T-cell-tolerizing peptides have been designed to induce immunologic tolerance via binding to MHC class II molecules on antigen presenting cells, with subsequent upregulation of regulatory T-cells.

View Article: PubMed Central - PubMed

Affiliation: Creticos Research Group, Crownsville, Maryland USA ; Division of Allergy & Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, Maryland USA.

ABSTRACT
Synthetic peptide immuno-regulatory epitopes (SPIRE) represent a new class of therapeutics for allergen immunotherapy that offer the potential to suppress the IgE-mediated allergic disease process through induction of T-cell tolerance. These synthetic T-cell-tolerizing peptides have been designed to induce immunologic tolerance via binding to MHC class II molecules on antigen presenting cells, with subsequent upregulation of regulatory T-cells.

No MeSH data available.


Related in: MedlinePlus